Cargando…
GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome
Wolfram syndrome (WS) is a rare neurodegenerative disorder that is mainly characterized by diabetes mellitus, optic nerve atrophy, deafness, and progressive brainstem degeneration. Treatment with GLP-1 receptor agonists has shown a promising anti-diabetic effect in WS treatment in both animal models...
Autores principales: | Seppa, Kadri, Toots, Maarja, Reimets, Riin, Jagomäe, Toomas, Koppel, Tuuliki, Pallase, Maia, Hasselholt, Stine, Krogsbæk Mikkelsen, Maiken, Randel Nyengaard, Jens, Vasar, Eero, Terasmaa, Anton, Plaas, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823542/ https://www.ncbi.nlm.nih.gov/pubmed/31673100 http://dx.doi.org/10.1038/s41598-019-52295-2 |
Ejemplares similares
-
Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome
por: Toots, Maarja, et al.
Publicado: (2018) -
Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model
por: Seppa, Kadri, et al.
Publicado: (2021) -
Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve atrophy and medullary degeneration
por: Plaas, Mario, et al.
Publicado: (2017) -
Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
por: Jagomäe, Toomas, et al.
Publicado: (2021) -
Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome
por: Jagomäe, Toomas, et al.
Publicado: (2023)